phase readout
saveNCT05665062: Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies
ACTIVE_NOT_RECRUITINGupdated 10d ago
community read0 votes
Sponsor: Synthekine. Phase: PHASE1. Conditions: CLL/SLL, NHL, Mantle Cell Lymphoma, Follicular Lymphoma, Large B-cell Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma
view source ↗
comments(0)
5-min edit window · permanent after that